Whipple’s Disease Market Research Report - Global Forecast till 2023

Whipple’s Disease Market Research Report - Global Forecast till 2023

ID: MRFR/HC/2762-HCRR | August, 2017 | Region: Global | 80 pages | Half-Cooked Research Reports

Whipple’s disease market information: by diagnosis (physical exam, biopsy, and others), by treatment (medications, supplements, and others), by end user- global forecast till 2023


FIGURE 1 GLOBAL WHIPPLE’S DISEASE MARKET SHARE BY END USER, 2016 (%)


 


Sources: The National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, The National Institute of Neurological Disorders and Stroke (NINDS), National Center for Biotechnology Information (NCBI), National Organization for Rare Disorders, Inc, Directorate of Industries, annual report, white paper, company presentation



Intended Audience



  • Whipple’s Disease Diagnostic and Treatment Supplies Companies

  • Whipple’s Disease Diagnostic and Treatment Supplies Providers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors




Research Methodology



 Sources: The National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, The National Institute of Neurological Disorders and Stroke (NINDS), National Center for Biotechnology Information (NCBI), National Organization for Rare Disorders, Inc, Directorate of Industries, annual report, white paper, company presentation



Market Synopsis of Global Whipple’s disease Market


Market Scenario


Whipple’s disease (WD) is a rare, chronic, systemic infectious bacterial disease caused by Tropheryma whipplei that affects gastrointestinal system, especially,  the small intestine. The infection may spread to any part of the body but mostly it affects the central nervous system, joints, lungs, heart, and eyes. Some common symptoms of this disease are weight loss, diarrhea, abdominal cramping and pain, weakness, fatigue, anemia, inflamed joints, and some other less common symptoms. The prevalence is one in one million people. The prevalence of this diseases is more in men than women.


Ongoing research and clinical trial to find effective cure drive the growth of market. Advancement in medical technology and increasing awareness about this disease boost the market growth.


The global Whipple’s disease market is expected to grow at the CAGR of ~3.1% during the forecast period and is estimated to reach USD 255.3 million by 2023.



Segments                                                                                                                                          


The global Whipple’s disease market is segmented on the basis of diagnosis, which includes physical exam, biopsy, blood tests, polymerase chain reaction, endoscopy, and others. Biopsy plays important role in diagnosis of this disorder, these tests include needle biopsy, CT-guided biopsy, ultrasound-guided biopsy, aspiration biopsy (fine-needle aspiration), skin biopsy, surgical biopsy, and others. Blood tests sub-segmented into Complete blood count (CBC), Red Blood Cell Count (RBC), serum albumin test, total protein test, and others.


On the basis of treatments, the market is segmented into medications, supplements, and others. Medications is sub-segmented into Intravenous (IV) ceftriaxone (Rocephin), Intravenous (IV) penicillin, sulfamethoxazole-trimethoprim, SMX-TMP, oxycycline (Vibramycin), hydroxychloroquine (Plaquenil), and others. Supplements include vitamin supplements, mineral supplements, and others.


On the basis of end user, it is segmented into hospitals & clinics, academic institutes, medical research centers, and others.



Regional Analysis of the Global Whipple’s Disease Market                  


The Americas holds the largest share in the global Whipple’s disease market. North American region, especially, the US dominates the market in this region. It is a rare disease and found in around less than one in million people in US. Some other factors such as advanced medical facilities, ongoing research and clinical trials, and availability of skilled health professionals. Increasing awareness about this disease in Latin America drives market growth in this region.


The new cases of this disease is increasing in Europe. Availability of advanced diagnostic and therapeutic options, high awareness among the European population, and availability of skilled medical professional drive the European market. Availability of cost-effective of treatment in East European countries, for instance,  Poland than the other parts of the region add fuel to the growing demand. Owing to availability of cost-effective treatment, patients from Western European countries and Russia travel to East and Central European countries to treat this disease.


Asia Pacific region shows low prevalence of the disease. Increasing awareness about this disease in the Asian population leads the market growth. The rapidly developing healthcare sector is another major driver of the market. Due to rapid economic growth, rising middle class population, and their spending on healthcare and related services add fuel to the growth of this market.


Owing to lack of awareness about the disease, slow healthcare infrastructure development, and limited access to required medical facilities, the Middle East & Africa market is growing slower as compared to the global average. On the other hand, due to developed healthcare facilities and government support to improve public health, the Middle East countries such as the UAE dominates market of this region.



Key Players in the Global Whipple’s Disease Market                                  


Some of the key players in this market: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein, Inc (US), Pfizer Inc. (US)

1.    Report Prologue

2.    Introduction

      2.1    Definition

      2.2    Scope of the Study

            2.2.1    Research Objective

            2.2.2    Assumptions

            2.2.3    Limitations

      2.3    Market Structure

      2.4.    Market Segmentation

3.    Research Methodology

      3.1    Research Process

      3.2    Primary Research

      3.3    Secondary Research

      3.4    Market Size Estimation

      3.5    Forecast Model

4.    Market Dynamics

      4.1    Drivers

      4.2    Restraints

      4.3    Opportunities

      4.4    Mega Trends

      4.5    Macroeconomic Indicators

5.    Market Factor Analysis

      5.1     Value Chain Analysis

      5.2     Porters Five Forces Analysis

      5.3     Demand & Supply: Gap Analysis

      5.4    Pricing analysis

      5.5    Investment Opportunity Analysis

      5.6    Merger and Acquisition Landscape

      5.7    Upcoming Trends

6.    Global Whipple’s Disease Market by Diagnosis

      6.1     Physical exam    

      6.2    Biopsy

            6.2.1    Needle biopsy

            6.2.2    CT-guided biopsy

            6.2.3    Ultrasound-guided biopsy

            6.2.4    Aspiration biopsy (fine-needle aspiration)

            6.2.5    Skin biopsy

            6.2.6    Surgical biopsy

            6.2.7    Others

      6.3    Blood tests

            6.3.1    Complete blood count (CBC)

            6.3.2    Red Blood Cell Count (RBC)

            6.3.3    Serum Albumin Test

            6.3.4    Total protein test

            6.3.5    Others

      6.4    Polymerase Chain Reaction

      6.5    Endoscopy

      6.6    Others

7.    Global Whipple’s Disease Market by Treatment

      7.1    Medications

            7.1.1    Intravenous (IV) ceftriaxone (Rocephin)

            7.1.2    Intravenous (IV) penicillin

            7.1.3    Sulfamethoxazole-trimethoprim

            7.1.4    SMX-TMP

            7.1.5    Oxycycline (Vibramycin)

            7.1.6    Hydroxychloroquine (Plaquenil)

            7.1.7    Others    

      7.2     Supplements

            7.2.1    Vitamin supplements

            7.2.2    Mineral supplements

            7.2.3    Others

      7.3    Others

8.    Global Whipple’s Disease Market by End User

      8.1    Hospital and clinics

      8.2    Academic institutes

      8.3    Medical Research centers

      8.4    Others

9.    Global Whipple’s Disease Market by Region

      9.1    Introduction

      9.2    Americas

            9.2.1    North America

                9.2.1.1 The US

                9.2.1.2 Canada

            9.2.2    Latin America

      9.3    Europe

            9.3.1    Western Europe

                9.3.1.1 Germany

                9.3.1.2 France

                9.3.1.3 Italy

                9.3.1.4 Spain

                9.3.1.5 UK

                9.3.1.6 Rest of Western Europe

            9.3.2    Eastern Europe

      9.4    Asia

            9.4.1    China

            9.4.2    India

            9.4.3    Japan

            9.4.4    South Korea

            9.4.5    Rest of Asia

      9.5    Pacific

      9.6    Middle East & Africa

            9.6.1    UAE

            9.6.2    Saudi Arabia

            9.6.3    Egypt

            9.6.4    Rest of the Middle East & Africa

10.     Competitive Landscape

11.    Company Profile


      11.1    AbbVie Inc.

            11.1.1    Overview    

            11.1.2    Product/Business Segment Overview    

            11.1.3    Financial Updates    

            11.1.4    Key Developments    

      11.2    Allergan

            11.2.1    Overview    

            11.2.2    Product/Business Segment Overview    

            11.2.3    Financial Updates    

            11.2.4    Key Developments    

      11.3   Bayer AG

            11.3.1    Overview    

            11.3.2    Product/Business Segment Overview    

            11.3.3    Financial Updates

            11.3.4     Key Developments        

      11.4    Bristol-Myers Squibb Company

            11.4.1    Overview    

            11.4.2    Product/Business Segment Overview    

            11.4.3    Financial Updates

            11.4.4     Key Developments       

      11.5    F. Hoffmann-La Roche Ltd

            11.5.1    Overview    

            11.5.2    Product/Business Segment Overview    

            11.5.3    Financial Updates    

            11.5.4    Key Developments    

      11.6    Henry Schein, Inc

            11.6.1    Overview    

            11.6.2    Product/Business Segment Overview    

            11.6.3    Financial Updates    

            11.6.4    Key Developments    

      11.7    Henry Schein, Inc

            11.7.1    Company Overview    

            11.7.2    Product/Business Segment Overview    

            11.7.3    Financial Updates    

            11.7.4    Key Development    

      11.8    Others

12.    Conclusion

      12.1    Key findings

            12.1.1    From CEO’s viewpoint

            12.1.2    Unmet Needs of the Market

      12.2    Key Companies to Watch

      12.3    Prediction of Whipple’s Disease Market

13.    Appendix